£30.00
This preparation combines CJC-1295 without DAC, a modified 29-amino-acid growth-hormone-releasing hormone analogue, with Ipamorelin, a selective pentapeptide agonist of the growth hormone secretagogue receptor. The two are supplied together as a single 10 mg lyophilised vial for in-vitro work in which both points of the same signalling axis are examined under one experimental condition.
This preparation combines CJC-1295 without DAC, a modified 29-amino-acid growth-hormone-releasing hormone analogue, with Ipamorelin, a selective pentapeptide agonist of the growth hormone secretagogue receptor. The two are supplied together as a single 10 mg lyophilised vial for in-vitro work in which both points of the same signalling axis are examined under one experimental condition.
| Format | Vial |
|---|---|
| Strength | 10mg |
